Sionna Therapeutics, Inc.

Developing novel NBD1 stabilizers and CFTR modulators to treat cystic fibrosis.

SION | US

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 21 HICKORY DRIVE, SUITE 500, 2451 WALTHAM
Website:: https://www.sionnatx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing transformative treatments for cystic fibrosis (CF). The company's mission is to normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Its novel approach centers on stabilizing the protein's nucleotide-binding domain 1 (NBD1), which directly targets the defect caused by F508del, the most common CF-causing mutation. Sionna is advancing a pipeline of proprietary small molecule NBD1 stabilizers, such as SION-719, and a portfolio of complementary CFTR modulators designed to work synergistically. The ultimate goal is to restore CFTR function to near-normal levels, revolutionizing the treatment paradigm for patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Sionna Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sionna Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Sionna Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Celon Pharma S.A. Researches, develops, and markets innovative drugs for oncology and neurology.	Poland	CLN
CEL SCI CORP Develops immunotherapies for cancer, autoimmune, and infectious diseases.	United States of America	CVM
Celularity Inc Develops off-the-shelf cell therapies from placentas for cancer and aging-related diseases.	United States of America	CELU
Centessa Pharmaceuticals plc Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.	United States of America	CNTA
CERO THERAPEUTICS HOLDINGS, INC. Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.	United States of America	CERO
CervoMed Inc. Developing CNS therapeutics for neurodegenerative diseases like dementia with Lewy bodies.	United States of America	CRVO
Cessatech A/S Develops a non-invasive nasal spray for acute pain relief in children during medical procedures.	Denmark	CESSA
CG Invites Co., Ltd. Biopharma advancing precision medicine with drugs, mRNA vaccines, and digital therapeutics.	South Korea	083790
CG Oncology, Inc. Developing bladder-sparing oncolytic immunotherapies for patients with bladder cancer.	United States of America	CGON
CHA Vaccine Research Institute Develops vaccines and immunotherapies for infectious diseases and cancer using proprietary platforms.	South Korea	261780